Denali Therapeutics (DNLI) Expected to Announce Quarterly Earnings on Monday

Key Points

• Denali Therapeutics will report Q1 2026 results before the market opens on May 11, with analysts expecting EPS of ($0.73) and revenue of $2.571 million; the earnings call is scheduled for May 13 at 4:00 PM ET.
• Analysts project roughly -$3 EPS for both the current and next fiscal years, while Denali’s most recent quarter reported ($0.73) EPS, slightly beating estimates.
• The stock has a market capitalization of $2.90 billion, an average analyst rating of “Moderate Buy” with a $35 target, and institutional investors own about 92.92% of the shares.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) is anticipated to announce its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($0.73) per share and revenue of $2.5710 million for the quarter. Parties can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same period in the previous year, the firm earned ($0.67) EPS. On average, analysts expect Denali Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI opened at $18.30 on Monday. The stock's 50-day simple moving average is $20.26 and its two-hundred day simple moving average is $18.80. Denali Therapeutics has a twelve month low of $12.58 and a twelve month high of $23.77. The firm has a market capitalization of $2.90 billion, a P/E ratio of -6.16 and a beta of 0.99. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Institutional Trading of Denali Therapeutics

A number of hedge funds have recently bought and sold shares of DNLI. Headlands Technologies LLC bought a new position in Denali Therapeutics during the second quarter valued at approximately $26,000. State of Wyoming bought a new stake in shares of Denali Therapeutics in the 2nd quarter worth approximately $29,000. Johnson Financial Group Inc. bought a new stake in shares of Denali Therapeutics in the 3rd quarter worth approximately $29,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Denali Therapeutics in the 4th quarter valued at $57,000. Finally, Quarry LP purchased a new stake in shares of Denali Therapeutics in the 3rd quarter valued at $64,000. Institutional investors own 92.92% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. HC Wainwright upped their price objective on shares of Denali Therapeutics from $32.00 to $42.00 and gave the stock a "buy" rating in a research report on Thursday, March 26th. Wall Street Zen lowered shares of Denali Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, April 25th. Wolfe Research started coverage on shares of Denali Therapeutics in a research note on Monday, February 23rd. They issued a "peer perform" rating for the company. Morgan Stanley raised their price objective on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an "overweight" rating in a research report on Thursday, March 26th. Finally, Leerink Partners dropped their price objective on shares of Denali Therapeutics from $40.00 to $35.00 and set an "outperform" rating for the company in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $35.00.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.